23I Stock Overview A biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Intra-Cellular Therapies, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Intra-Cellular Therapies Historical stock prices Current Share Price US$80.00 52 Week High US$87.00 52 Week Low US$58.30 Beta 0.70 1 Month Change -0.62% 3 Month Change 22.14% 1 Year Change 26.18% 3 Year Change 99.75% 5 Year Change 241.88% Change since IPO 556.49%
Recent News & Updates
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting Dec 11
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy Dec 03
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia Nov 05
Intra-Cellular Therapies, Inc. Raises Financial Guidance for the Full Year 2024 Nov 02
Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.25 loss in 3Q 2023) Nov 01
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.45 loss in 2Q 2023) Aug 08 See more updates
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting Dec 11
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy Dec 03
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia Nov 05
Intra-Cellular Therapies, Inc. Raises Financial Guidance for the Full Year 2024 Nov 02
Third quarter 2024 earnings released: US$0.25 loss per share (vs US$0.25 loss in 3Q 2023) Nov 01
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.45 loss in 2Q 2023) Aug 08 Intra-Cellular Therapies, Inc. Raises Sales Guidance for 2024
Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 2000 Dynamic Index Jul 03
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder Jun 18
Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024 May 09
First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.46 loss in 1Q 2023) May 07
Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 14, 2024 May 01 Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million. Apr 19
Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $500.000068 million. Apr 18
New minor risk - Shareholder dilution Apr 17
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder Apr 16 Intra-Cellular Therapies, Inc. Announces Retirement of Larry Hineline as Chief Financial Officer
Full year 2023 earnings released: US$1.46 loss per share (vs US$2.73 loss in FY 2022) Feb 23
New minor risk - Shareholder dilution Feb 23
Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2024 Feb 23
Forecast to breakeven in 2025 Feb 08
EVP & Chief Commercial Officer recently sold €801k worth of stock Nov 09
Intra-Cellular Therapies, Inc. Provides Sales Guidance for the Fiscal Year 2023 Nov 03
Third quarter 2023 earnings released: US$0.25 loss per share (vs US$0.57 loss in 3Q 2022) Nov 03
Intra-Cellular Therapies, Inc. Provides Earnings Guidance for the Full Year 2023 Aug 04
Second quarter 2023 earnings released: US$0.45 loss per share (vs US$0.92 loss in 2Q 2022) Aug 04
Forecast to breakeven in 2025 Jul 06
Intra-Cellular Therapies, Inc. Announces CAPLYTA Data Presentations At the American Society of Clinical Psychopharmacology Annual Meeting Jun 01
Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Year 2023 May 05
First quarter 2023 earnings released: US$0.46 loss per share (vs US$0.78 loss in 1Q 2022) May 05
Full year 2022 earnings released: US$2.73 loss per share (vs US$3.50 loss in FY 2021) Mar 02
Forecast breakeven date pushed back to 2025 Feb 01
Forecast breakeven date pushed back to 2025 Jan 27
Independent Director recently sold €240k worth of stock Dec 23
Independent Director recently sold €523k worth of stock Nov 16
Independent Director recently sold €523k worth of stock Nov 10
Third quarter 2022 earnings released: US$0.57 loss per share (vs US$0.94 loss in 3Q 2021) Nov 04
Independent Director recently sold €573k worth of stock Aug 14
Second quarter 2022 earnings released: US$0.92 loss per share (vs US$0.85 loss in 2Q 2021) Aug 10
First quarter 2022 earnings released: US$0.78 loss per share (vs US$0.65 loss in 1Q 2021) May 11
Intra-Cellular Therapies, Inc. Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations Apr 26 Intra-Cellular Therapies, Inc., Annual General Meeting, Jun 09, 2022
Independent Director recently sold €736k worth of stock Mar 17
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 02
Forecast to breakeven in 2024 Jan 01
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults Dec 21
Third quarter 2021 earnings released: US$0.94 loss per share (vs US$0.79 loss in 3Q 2020) Nov 10
Intra-Cellular Therapies, Inc. Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry Sep 29
Second quarter 2021 earnings released: US$0.85 loss per share (vs US$0.96 loss in 2Q 2020) Aug 10
Forecast to breakeven in 2023 Aug 10
High number of new directors Jul 31 Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) dropped from Russell 3000E Value Index
First quarter 2021 earnings released: US$0.65 loss per share (vs US$0.73 loss in 1Q 2020) May 11
Intra-Cellular Therapies Announces FDA Acceptance of Caplyta (Lumateperone) SNDAs for the Treatment of Bipolar Depression May 04
Revenue beats expectations Feb 26
Intra-Cellular Therapies Announces Expansion of Pipeline with the Introduction of New Molecular Entity, ITI-1284 Feb 25
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression Feb 23
New 90-day high: €32.85 Feb 20
New 90-day high: €29.02 Feb 04
Intra-Cellular Therapies, Inc. Announces the Publication of Results from the CAPLYTA Clinical Trial (ITI-007-303) Jan 22
New 90-day high: €27.41 Jan 13
Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder Dec 30
New 90-day high: €23.82 Dec 23
Senior VP of Finance recently sold €174k worth of stock Nov 14
Revenue beats expectations Nov 11
Intra-Cellular Therapies, Inc. Announces Executive Changes Oct 03
Intra-Cellular Therapies, Inc. Announces Executive Changes Oct 02
Intra-Cellular Therapies, Inc. has completed a Follow-on Equity Offering in the amount of $350.00001 million. Sep 11
New 90-day low - €15.16 Sep 01
New 90-day low - €16.08 Aug 10
First half earnings released Aug 10 Shareholder Returns 23I DE Pharmaceuticals DE Market 7D 0% 1.7% 0.3% 1Y 26.2% -16.2% 8.4%
See full shareholder returns
Return vs Market: 23I exceeded the German Market which returned 8.4% over the past year.
Price Volatility Is 23I's price volatile compared to industry and market? 23I volatility 23I Average Weekly Movement 5.4% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 23I has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 23I's weekly volatility (5%) has been stable over the past year.
About the Company Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications.
Show more Intra-Cellular Therapies, Inc. Fundamentals Summary How do Intra-Cellular Therapies's earnings and revenue compare to its market cap? 23I fundamental statistics Market cap €8.55b Earnings (TTM ) -€83.39m Revenue (TTM ) €592.55m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 23I income statement (TTM ) Revenue US$613.73m Cost of Revenue US$263.87m Gross Profit US$349.86m Other Expenses US$436.23m Earnings -US$86.37m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 15:52 End of Day Share Price 2024/12/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Intra-Cellular Therapies, Inc. is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Joel Beatty Baird Ishan Majumdar Baptista Research Jason Matthew Gerberry BofA Global Research
Show 25 more analysts 
